Investment Banking Update: Notable March Transactions and Cautious Optimism Ahead BlogInvestment Banking TeamApril 3, 2023Investment Banking, Capital, Markets, Investing, Biotech, Medtech
Healthcare Companies Venture Back into Public Markets BlogInvestment Banking TeamFebruary 27, 2023Investment Banking, Capital, Markets, Investing, Biotech, Medtech
Prepare for What the Markets Could Bring BlogInvestment Banking TeamJanuary 18, 2023Investment Banking, Capital, Markets, Investing, Biotech, Medtech
Inefficient Markets: Public Market Dislocations and Negative Biotech Enterprise Values BlogInvestment Banking TeamMay 31, 2022BioPharma, IPO, Investing
Biopharma Companies Don’t Need to Be Public to Survive BlogInvestment Banking TeamApril 14, 2022BioPharma, IPO, Investing
Back Bay in Wall Street Journal, Pro Venture Capital: Medical-Device IPOs, Acquisitions Jumped in 2021 Media CoverageBack Bay Life Science AdvisorsJanuary 15, 2022Investing, Medical Device, IPOs, M&A
Medtech Investors Take Note Investment Banking UpdateBack Bay Life Science AdvisorsMarch 8, 2021MedTech, HealthTech, Investing, Development, Investment Banking
